Client NewsRoquefort Therapeutics PLC: Results of AGM
Roquefort Therapeutics (LSE:ROQ), is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.
Roquefort is pleased to announce that at the Company’s Annual General Meeting (“AGM”) held earlier today, all resolutions proposed were duly passed.
The total number of ordinary shares in issue on 28 June 2022, the deadline for casting votes by proxy in advance of the AGM, was 71,900,000 shares. 23.64% of voting capital was instructed in respect of the resolutions put to the AGM.
For more information please follow the link below:
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.